Lebrikizumab shows potential for atopic dermatitis
19 Mar 2020
byAudrey Abella
The novel, high-affinity, monoclonal antibody lebrikizumab demonstrated significant efficacy in a dose-dependent manner across a range of clinical manifestations of moderate-to-severe atopic dermatitis (AD), including pruritus and quality of life (QoL), a phase IIb study has shown.